Savara (Nasdaq: SVRA) has released encouraging long-term Phase 3 data suggesting that patients receiving molgramostim for an autoimmune pulmonary condition continue to see improved lung function and respiratory health. Announced in Langhorne, Pennsylvania, the results spotlight a potential breakthrough for individuals affected by persistent breathing challenges.